Who we are
SynOx was founded with a clear purpose: to improve the lives of people living with TGCT. We believe that although TGCT is a rare condition, the people affected by it deserve the same commitment to innovation, research and support as anyone living with a more common disease.
Behind every TGCT diagnosis is a person whose daily life has changed. Living with pain, reduced mobility and uncertainty can affect far more than a joint – it can affect work, family life, independence and confidence. Those experiences help shape the science we pursue and the decisions we make every day.
As a biotechnology company focused on macrophage biology, we’re working to develop new treatment options for people living with TGCT and to advance understanding of this rare disease.
Our team
SynOx brings together an experienced, multidisciplinary team with expertise spanning science, medicine, drug development, commercialisation, finance and operations. We combine deep industry experience with the agility and focus of a growing biotechnology company.
Across our leadership team, Board and wider organisation, we share a common purpose: to improve the lives of people living with TGCT. As we advance emactuzumab and prepare for the next stage of SynOx’s growth, we are building the capabilities, culture and partnerships needed to turn strong science into meaningful outcomes for patients.
Send us a message
Join us
At SynOx, we are building a company where talented people can do their best work and see the impact of what they contribute. We are ambitious about the science, open in how we work and pragmatic in how we make decisions.
As a growing biotechnology company, everyone has the opportunity to work across functions, take ownership and help shape how we operate. We value people who are curious, collaborative and willing to challenge assumptions, while staying focused on what matters most: improving the lives of people living with TGCT.
